Skip to content
StockMarketAgent
Direct answer
ALNY trades against a final fair-value range of $387.78-$974.55, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $388, high $975, with mid-point at $666.
Stock analysis

ALNY ALNY fair value $388–$975

ALNY
By StockMarketAgent.AI team· supervised by
Analizzato: 2026-05-13Prossimo aggiornamento: 2026-08-13Methodology v2.5Review: automatedArchetype: Hyper-growth
View archive
Prezzo
$292.03
▲ +373.72 (+127.97%)
Valore equo
$666
$388–$975
Valutazione
Acquisto forte
confidence 86/100
Potenziale rialzo
+128.0%
upside to fair value
Margine di Sicurezza
$565.89
MoS level · 15%
Capitalizzazione
$39.0B
P/E fwd 21.0
Fallback in ingleseIT
Mostrando la fonte in inglese mentre traduciamo
Questo report non è ancora stato tradotto. Aggiorna tra qualche minuto una volta che la coda di traduzione avrà recuperato.

§1 Sintesi

  • Composite fair value $666 with high case $975.
  • Implied upside of 128.0% to fair value.
  • Moat 9/10 · confidence 86/100 · Hyper-growth.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$666
Margin of safety
+56.1%
Confidence
86/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$292.03Price
Low $387.78
Mid $665.75
High $974.55

ALNY trades against a final fair-value range of $387.78-$974.55, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • First-mover advantage and foundational IP
    First-mover advantage and foundational IP in RNA interference.
  • Established commercial infrastructure across global
    Established commercial infrastructure across global rare disease markets.
  • Bull thesis
    The market is pricing ALNY as a mature rare-disease biotech rather than an inflecting hyper-growth platform.

§2 Scenario ribassista

Under an extreme stress test where the prevalent disease pipeline yields zero commercial value, ALNY reverts to a mature rare-disease biotech. This drops terminal multiples to 15x and compresses peak margins to 25%, resulting in our $387 bear caseBear caseThe worst-realistic outcome — what happens if our top three risks materialize together. Used to set the floor of our fair-value range and inform position sizing. floor.

Come questa tesi può fallire

Prevalent Disease Pipeline Failure

25%· Medium

Key prevalent indication readouts, such as hypertension or obesity, fail to show superiority, restricting TAM strictly to rare diseases.

FV impact
Compresses valuation to $387 floor.
Trigger
12-24 months

Margin Squeeze from Pricing Pressure

· Medium

IRA and competitive pressure limit peak operating margins below the projected 35%, trapping the firm in a lower-return profile.

FV impact
Drops valuation to $480 FCFF DCF baseline.
Trigger
24-36 months

Genetic Medicine Disruption

· Low

CRISPR and base editing therapies permanently cure indications ALNY currently manages chronically, destroying chronic recurring revenue streams.

FV impact
Terminal growth drops to 0%, valuation below $300.
Trigger
5+ years
Segnali di allerta precoce da monitorare
MetricaAttualeSoglia di attivazione
Delay or failure in Zilebesiran clinical readouts.MonitorDeterioration versus the report thesis
Operating margins failing to expand toward the 35% target.MonitorDeterioration versus the report thesis
R&D expanding disproportionately to revenue growth.MonitorDeterioration versus the report thesis
Increased competitive trial data from gene-editing peers.MonitorDeterioration versus the report thesis
Unexpected regulatory pushback on novel delivery mechanisms.MonitorDeterioration versus the report thesis

§3 Storia finanziaria

Conto economico — ultimi sei periodi
VoceT−0T−1T−2T−3CAGR
Periodo2022-12-312023-12-312024-12-312025-12-31Trend
Ricavi$1.04B$1.83B$2.25B$3.71B+53.0%
Utile lordo$868.6M$1.52B$1.92B$3.03B+51.7%
Reddito operativo$-785.1M$-282.2M$-176.9M$501.6M—
Utile netto$-1.13B$-440.2M$-278.2M$313.7M—
EPS (diluito)$-9.30$-3.52$-2.18$2.33—
EBITDA$-926.6M$-258.2M$-178.8M$631.4M—
R&S$883.0M$1.00B$1.13B$1.32B+14.3%
SG&A$770.7M$795.6M$975.5M$1.21B+16.3%

Punteggi di qualità

OCF / Utile netto
1.67×
>1 indica alta qualità degli utili
Soglia di qualità contabile
Fail
Soglia corretta per settore
ROIC
22.0%
Rendimento del capitale investito
Sezione 3

Numbers analysis

Flusso di cassa

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Allocazione del capitale

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Abbonati individuali — da §4 in poi11 sezioni in più

Leggi l'analisi completa — 11 sezioni in più.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Report completo per ogni ticker coperto
24 mesi di archivio rating
Briefing della watchlist + avvisi di variazione del rating
Esportazione PDF + DOCX in qualsiasi lingua
Inizia la prova gratuita
Annulla in qualsiasi momento.
FAQ

ALNY — frequently asked questions

  1. Based on our latest analysis, ALNY looks meaningfully undervalued. The current price is $292 versus a composite fair-value midpoint of $666 (range $388–$975), which implies roughly 128.0% upside to the midpoint.

Related coverage

Names readers of ALNY also follow

Same archetype: hyper-growth